- .

(Seoul=NSP NEWS) = LG CNS has moved to scale up its digital healthcare business through a strategic partnership with CHA Biotech(085660), the holding company of the CHA Bio Group.

The company said it has made a 10 billion won (about $73 million) equity investment in CHA Biotech and signed a partnership agreement focused on AX and DX collaboration.

Under the agreement, the two companies will establish a joint working council. As short-term initiatives, they plan to migrate the group’s cloud infrastructure and build a smart big data platform that integrates data across affiliates, including hospitals and pharmaceutical units.

They will also work to upgrade therapeutic manufacturing facilities with AI-based systems, aiming to optimize production processes. Over the medium to long term, the partners plan to jointly commercialize connected healthcare services built on specialized AI models.

The services will analyze health and lifestyle data generated from hospitals, residential spaces and wearable devices. When potential risk signals are detected, the system will connect users with medical professionals and provide guidance for clinical care and emergency response.

LG CNS said it plans to develop a healthcare-specific small large language model (sLLM) and a data collection and management platform using EXAONE, the AI model developed by LG AI Research.

The companies are also reviewing options for global expansion by leveraging CHA Bio Group’s overseas hospital network, which spans the United States, Singapore, Australia and Japan.

Looking ahead, LG CNS said it will explore opportunities to expand into related industries by building on the data and expertise accumulated through platform operations.

By Eun-young Huh(eunyoung114@nspna.com) and Bok-hyun Lee(bhlee2016@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved. Prohibits using to train AI models.